Delcath Systems (NASDAQ:DCTH) Price Target Raised to $25.00

Delcath Systems (NASDAQ:DCTH) had its target price raised by BTIG Research from $21.00 to $25.00 in a report published on Monday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

Other research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target (up from $30.00) on shares of Delcath Systems in a report on Friday, August 7th. Weiss Ratings downgraded Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Finally, Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Delcath Systems currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Delcath Systems Trading Up 8.3%

DCTH stock opened at $21.77 on Monday. The firm has a 50 day moving average of $15.71 and a 200-day moving average of $12.59. Delcath Systems has a 12 month low of $8.12 and a 12 month high of $22.33. The firm has a market capitalization of $755.40 million, a P/E ratio of 136.06 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26. The business had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. Sell-side analysts predict that Delcath Systems will post -0.17 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

A number of hedge funds and other institutional investors have recently bought and sold shares of DCTH. Russell Investments Group Ltd. increased its holdings in shares of Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after buying an additional 21,069 shares during the last quarter. Alps Advisors Inc. raised its position in shares of Delcath Systems by 30.3% during the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company’s stock valued at $729,000 after buying an additional 10,600 shares in the last quarter. Kopp Family Office LLC purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at $450,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Delcath Systems during the 2nd quarter valued at $48,000. Finally, IFP Advisors Inc bought a new stake in shares of Delcath Systems during the 2nd quarter worth $52,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems News Roundup

These are some of the DCTH news items that stood out recently:

• Positive Sentiment: HC Wainwright raised its price target to $36 from $32 and reaffirmed its Buy rating, signaling substantial potential upside in the firm’s view. Delcath Systems Gets a Buy from H.C. Wainwright
• Positive Sentiment: HC Wainwright increased its annual EPS estimates for 2028, 2029 and 2030 to $0.68, $1.08 and $1.61, respectively. The upgrades reinforce expectations for improving longer-term profitability.
• Negative Sentiment: HC Wainwright trimmed its Q2 2027 EPS forecast to $0.11 from $0.12, a small near-term estimate reduction that contrasts with its higher longer-term projections.

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.